| 1 |
35436627 | Attenuated cell-cycle division protein 2 and elevated mitotic roles of polo-like kinase 1 characterize deficient myoblast fusion in peripheral arterial disease. | 2022 Jun 18 |
1 |
| 2 |
33638254 | Design, synthesis, and biological evaluation of novel 4,4-difluoro-1-methyl-N, 6-diphenyl-5, 6-dihydro-4H-pyrimido [4, 5-b] [1, 2, 4] triazolo [4, 3-d] [1, 4] diazepin-8-amine derivatives as potential BRD4 inhibitors. | 2021 May |
1 |
| 3 |
34376582 | Potent Synergistic Effect on C-Myc-Driven Colorectal Cancers Using a Novel Indole-Substituted Quinoline with a Plk1 Inhibitor. | 2021 Oct |
2 |
| 4 |
34493069 | Identification of novel microtubule inhibitors effective in fission yeast and human cells and their effects on breast cancer cell lines. | 2021 Sep |
1 |
| 5 |
34700228 | Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer. | 2021 Dec |
1 |
| 6 |
32231733 | The dual role of BI 2536, a small-molecule inhibitor that targets PLK1, in induction of apoptosis and attenuation of autophagy in neuroblastoma cells. | 2020 |
3 |
| 7 |
32496211 | Antiviral activity of PLK1-targeting siRNA delivered by lipid nanoparticles in HBV-infected hepatocytes. | 2020 |
1 |
| 8 |
32645997 | DrugSniper, a Tool to Exploit Loss-Of-Function Screens, Identifies CREBBP as a Predictive Biomarker of VOLASERTIB in Small Cell Lung Carcinoma (SCLC). | 2020 Jul 7 |
1 |
| 9 |
32962858 | Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC. | 2020 Dec 10 |
1 |
| 10 |
32970049 | A new genre of fluorescence recovery assay to evaluate polo-like kinase 1 ATP-competitive inhibitors. | 2020 Sep 28 |
3 |
| 11 |
33584305 | Dual Inhibition of γ-Tubulin and Plk1 Induces Mitotic Cell Death. | 2020 |
1 |
| 12 |
30488440 | Effect of PLK1 inhibition on cisplatin-resistant gastric cancer cells. | 2019 May |
1 |
| 13 |
30800581 | An oncoinformatics study to predict the inhibitory potential of recent FDA-approved anti-cancer drugs against human Polo-like kinase 1 enzyme: a step towards dual-target cancer medication. | 2019 Mar |
1 |
| 14 |
30836927 | Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo. | 2019 |
7 |
| 15 |
30876762 | A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma. | 2019 Mar |
1 |
| 16 |
30996295 | Therapeutic potential of PLK1 inhibition in triple-negative breast cancer. | 2019 Sep |
3 |
| 17 |
31118282 | Role of Polo-like kinase 1 in the regulation of the action of p31comet in the disassembly of mitotic checkpoint complexes. | 2019 Jun 11 |
1 |
| 18 |
31227645 | Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia. | 2019 Sep |
1 |
| 19 |
29393385 | BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells. | 2018 Mar |
3 |
| 20 |
29437878 | Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer. | 2018 Apr |
1 |
| 21 |
29476067 | BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1. | 2018 Feb 23 |
1 |
| 22 |
29525435 | Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups. | 2018 Apr 25 |
1 |
| 23 |
29541386 | ATP-competitive Plk1 inhibitors induce caspase 3-mediated Plk1 cleavage and activation in hematopoietic cell lines. | 2018 Feb 16 |
2 |
| 24 |
30102854 | Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. | 2018 Sep 21 |
1 |
| 25 |
30217950 | Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells. | 2018 Dec |
1 |
| 26 |
30299205 | Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer. | 2018 |
1 |
| 27 |
27463838 | Defeat mutant KRAS with synthetic lethality. | 2017 Oct 2 |
1 |
| 28 |
27671301 | Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma. | 2017 |
2 |
| 29 |
28184925 | Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation. | 2017 Mar |
1 |
| 30 |
28212994 | An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). | 2017 Feb |
4 |
| 31 |
28445592 | Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication. | 2017 Dec |
2 |
| 32 |
28586718 | Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor. | 2017 Sep 8 |
1 |
| 33 |
28628916 | Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536. | 2017 |
2 |
| 34 |
26046302 | Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis. | 2016 Feb 23 |
1 |
| 35 |
26634982 | Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain. | 2016 Apr 15 |
1 |
| 36 |
26713885 | Evaluation of Polo-like kinase 1 as a potential therapeutic target in Merkel cell carcinoma. | 2016 Apr |
1 |
| 37 |
26754547 | Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma. | 2016 Mar |
1 |
| 38 |
26900800 | Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer. | 2016 |
2 |
| 39 |
27582537 | Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma. | 2016 Oct 4 |
1 |
| 40 |
27713178 | Impact of Polo-like kinase 1 inhibitors on human adipose tissue-derived mesenchymal stem cells. | 2016 Dec 20 |
1 |
| 41 |
25505174 | Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer. | 2015 Jan 23 |
1 |
| 42 |
25524551 | Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells. | 2015 Feb 28 |
2 |
| 43 |
25565629 | Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy. | 2015 |
4 |
| 44 |
25697066 | Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. | 2015 Apr |
2 |
| 45 |
25917079 | Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma. | 2015 Aug 28 |
1 |
| 46 |
25925375 | The Catalytic Subunit of DNA-Dependent Protein Kinase Coordinates with Polo-Like Kinase 1 to Facilitate Mitotic Entry. | 2015 Apr |
2 |
| 47 |
25927139 | Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer. | 2015 |
2 |
| 48 |
25992548 | Application of RNAi to Genomic Drug Target Validation in Schistosomes. | 2015 May |
1 |
| 49 |
26191363 | BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536. | 2015 Jul 9 |
3 |
| 50 |
26349973 | BI2536--A PLK inhibitor augments paclitaxel efficacy in suppressing tamoxifen induced senescence and resistance in breast cancer cells. | 2015 Aug |
2 |